Nijhof, Inger S.
4 papers on CoChat
Most cited papers
- Verified
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine
Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research
Cited by 599
- Verified
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
Nijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., et al. (2015) · Clinical Cancer Research
Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research
Cited by 151
- Verified
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
Franssen, L. E., Nijhof, I. S., Couto, S., Levin, M.-D., Bos, G. M. J., Broijl, A., Klein, S. K., Ren, Y., Wang, M., Koene, H. R., et al. (2018) · Haematologica
Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors
Cited by 66
- Verified
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 41
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free